Abstract:To describe health-related quality of life (HRQoL) and health utility of persons with hemophilia B, and to determine the association of these measures with self-reported joint pain and motion limitation. The prospective, longitudinal Hemophilia Utilization Group Study (HUGS-Vb) recruited participants with hemophilia B from six U.S. Hemophilia Treatment Centers from June 2009 to September 2010. At initial interview, participants or their parent(s) answered questions regarding demographic and clinical characteristics, HRQoL, health utility and self-reported joint pain and motion limitation. HRQoL measures included Short Form-12 (SF-12) for adults and PedsQL for children. Health utility measures used were EQ-5D (adults) and visual analog scale (VAS). Seventy-seven participants (48% adults) were recruited. Adult mean SF-12 mental (MCS-12) and physical (PCS-12) component scores were 54.3 (±6.13) and 47.1 (±11.1) respectively. Participants with mild/moderate hemophilia (mean=50.4±9.0) had significantly better PCS-12 scores than those with severe hemophilia (mean=42.6±12.4) (P=0.0390). Mean EQ-5D and VAS scores were 0.85 (±0.16) and 85.5 (±11.1) respectively, with no significant differences between severity groups. PCS-12 and EQ-5D each negatively correlated with self-reported joint pain (PCS-12:P<0.0001, EQ-5D:P=0.0017) and motion limitation (PCS-12:P<0.0001, EQ-5D:P=0.0081); better HRQoL was associated with less severe pain or limitation. Pediatric mean total PedsQL score was 85.6 (±11.2) with physical (PF) and psychosocial functioning summary scores of 92 (±14.9) and 82 (±13.1) respectively. Mean VAS score was 88.6 (±14.3). No significant differences were found between severity groups. PF and VAS scores each negatively correlated with self-reported joint pain (PF:P=0.0127, VAS:P=0.0245) and motion limitation (PF:P=0.0009, VAS:P=0.0015). While previous HRQoL studies have examined hemophilia A and its associated clinical aspects, this is the first focusing on the hemophilia B population. As hemophilia A and B may have different clinical manifestations, HRQoL data on hemophilia B can help define disease burden in this group. One limitation is the current small sample size, which will increase as additional participants continue to be enrolled.

The value‐based healthcare approach to haemophilia: Development of outcome measures for the evaluation of care of people with haemophilia

Outcomes and outcome measures

Quality of Life in Haemophilia A: Hemophilia Utilization Group Study Va (Hugs-Va)

Outcome measures in hemophilia: current and future perspectives

Pnd47 the hemophilia utilization group study (hugs-vb): health-related quality of life in hemophilia b

Defining success in haemophilia care – Are we doing it right?

Development of the coreHEM mental health patient-reported outcome measure - A novel mental health outlook measure for people with haemophilia

Longitudinal Changes in Health-Related Quality of Life for Chronic Diseases: an Example from the Hemophilia Utilization Group Study Part Va (hugs Va)

Results from a Patients'-Clinicians' Project to Address the New Therapeutic Landscape

Disease Burden, Clinical Outcomes, and Quality of Life in People with Hemophilia A without Inhibitors in Europe: Analyses from CHESS II/CHESS PAEDs

A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.

Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia

Optimizing long-term joint health in the treatment of hemophilia

Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions

Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study

Humanistic burden of haemophilia A without inhibitors: A cross‐sectional analysis of the HemoLIFE study

Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions

Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals

Changes in Quality of Life, Adherence, and Kinesiophobia in Patients with Hemophilia Treated with Extended Half-Life Treatment: Final Results of the LongHest Project

Development and validation of a measure of disease-specific quality of life in young children with haemophilia

Disentangling the value equation: a step forward in value-based healthcare